An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of ABBV-383 in AL Amyloidosis

The purpose of this study is to see how safe and effective is the study drug, ABBV-383. ABBV-383 works by binding to a specific protein called B-cell maturation antigen, which is found on the surface of cells affected by amyloidosis. By engaging T-cells, a type of white blood cell, ABBV-383 helps activate the immune response to target and remove the abnormal proteins that cause amyloidosis. The study drug ABBV-383, is not approved by the U.S Food and Drug Administration (FDA).

Are you Eligible? (Inclusion Criteria)

• Must be 18 years or older - Must consent to fresh pretreatment bone marrow tumor biopsy or has adequate left over bone marrow tumor tissue that was collected within 12 weeks prior to screening - Cannot have history of drug or alcohol abuse within the last 6 months